Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

OnKure Therapeutics (OKUR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target.

Soumit Roy has given his Buy rating due to a combination of factors influencing OnKure Therapeutics. The recent updates from the ASCO 2025 conference highlighted significant developments in the HR+/HER2- metastatic breast cancer treatment landscape. OnKure’s OKI-219 is positioned to compete effectively in this rapidly evolving field, especially with its potential in combination therapies involving selective estrogen receptor degraders (SERDs) and CDK4/6 inhibitors.
Roy’s confidence in OnKure is further supported by the company’s strategic focus on reducing WT-PI3Kα-associated toxicities, which is a critical concern for oncologists. The anticipated data from the combination of OKI-219 with fulvestrant, expected in the second half of 2025, could redefine treatment protocols and enhance OnKure’s competitive edge. Additionally, OnKure’s financial position, with a cash reserve of $97 million, provides a solid foundation to support its ongoing research and development efforts.

According to TipRanks, Roy is an analyst with an average return of -26.4% and a 17.78% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Enliven Therapeutics, and IN8bio.